Statin Eligibility and Cardiovascular Risk Burden Assessed by Coronary Artery Calcium Score: Comparing the Two Guidelines in a Large Korean Cohort
Overview
Authors
Affiliations
Objective: To investigate the statin eligibility and the predictabilities for cardiovascular disease between AHA/ACC and ATPIII guidelines, comparing those results to concomitant coronary artery calcium scores (CACS) in a large cohort of Korean individuals who met statin-eligibility criteria.
Methods: Among 19,920 participants in a health screening program, eligibility for statin treatment was assessed by the two guidelines. The presence and extent of coronary artery calcification (CAC) was measured by multi-detector computed tomography and compared among the various groups defined by the two guidelines.
Results: Applying the new ACC/AHA guideline to the health screening cohort increased the statin-eligible population from 18.7% (as defined by ATP III) to 21.7%. Statin-eligible subjects as defined only by ACC/AHA guideline manifested a higher proportion of subjects with CAC compared with those meeting only ATP-III criteria even after adjustment for age and sex (47.1 vs. 33.8%, p<0.01). Statin-eligible subjects as defined by ACC/AHA guideline showed higher odds ratio for the presence of CACS>0 compared with those meeting ATP-III criteria {3.493 (3.245∼3.759) vs. 2.865 (2.653∼3.094)}, which was attenuated after adjusted for age and sex.
Conclusions: In this large Korean cohort, more subjects would have qualified for statin initiation under the new ACC/AHA guideline as compared with the proportion recommended for statin treatment by ATP III guideline. Among statin-eligible Korean health screening subjects, the new ACC/AHA guideline identified a greater extent of atherosclerosis as assessed by CACS as compared to ATP III guideline assessment.
Haq A, Walser-Kuntz E, Gamam A, Albers A, Bae A, Benson G Clin Cardiol. 2024; 47(2):e24231.
PMID: 38362951 PMC: 10870333. DOI: 10.1002/clc.24231.
Lee J, Lim H, Kim J, Kim H J Clin Neurol. 2021; 17(1):86-95.
PMID: 33480203 PMC: 7840335. DOI: 10.3988/jcn.2021.17.1.86.
Jarrah M, Ababneh M, Tawalbeh L, Hammoudeh A, Barukba H, Othman A Ann Med Surg (Lond). 2021; 61:148-154.
PMID: 33425348 PMC: 7782195. DOI: 10.1016/j.amsu.2020.12.036.
Elnaem M, Mohamed M, Huri H, Azarisman S, Elkalmi R J Pharm Bioallied Sci. 2017; 9(2):80-87.
PMID: 28717329 PMC: 5508420. DOI: 10.4103/jpbs.JPBS_30_17.
Moon B, Kim J, Kim J, Hyun Y, Park S, Oh H Endocrinol Metab (Seoul). 2016; 31(3):402-409.
PMID: 27586450 PMC: 5053052. DOI: 10.3803/EnM.2016.31.3.402.